Sivik Global Healthcare LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 166.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 80,000 shares of the company’s stock after buying an additional 50,000 shares during the period. Eli Lilly and makes up approximately 3.1% of Sivik Global Healthcare LLC’s portfolio, making the stock its 7th largest position. Sivik Global Healthcare LLC’s holdings in Eli Lilly and were worth $6,729,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of LLY. Comerica Securities Inc. raised its stake in Eli Lilly and by 4.8% in the first quarter. Comerica Securities Inc. now owns 4,602 shares of the company’s stock worth $387,000 after buying an additional 211 shares in the last quarter. AE Wealth Management LLC raised its stake in Eli Lilly and by 8.5% in the first quarter. AE Wealth Management LLC now owns 12,651 shares of the company’s stock worth $1,064,000 after buying an additional 991 shares in the last quarter. Fort Washington Investment Advisors Inc. OH raised its stake in Eli Lilly and by 0.5% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 57,033 shares of the company’s stock worth $4,797,000 after buying an additional 300 shares in the last quarter. Mastrapasqua Asset Management Inc. raised its stake in Eli Lilly and by 29.3% in the first quarter. Mastrapasqua Asset Management Inc. now owns 9,210 shares of the company’s stock worth $775,000 after buying an additional 2,085 shares in the last quarter. Finally, Neuberger Berman Group LLC raised its stake in Eli Lilly and by 15.2% in the first quarter. Neuberger Berman Group LLC now owns 2,368,858 shares of the company’s stock worth $199,245,000 after buying an additional 311,724 shares in the last quarter. 75.61% of the stock is owned by institutional investors.
Eli Lilly and Company (NYSE:LLY) opened at 81.15 on Friday. The firm has a market cap of $85.61 billion, a P/E ratio of 35.11 and a beta of 0.34. The firm’s 50-day moving average price is $82.91 and its 200 day moving average price is $81.72. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.86 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is presently 90.04%.
COPYRIGHT VIOLATION WARNING: “Sivik Global Healthcare LLC Acquires 50,000 Shares of Eli Lilly and Company (NYSE:LLY)” was posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/08/13/eli-lilly-and-company-nyselly-shares-bought-by-sivik-global-healthcare-llc-updated.html.
A number of research firms have commented on LLY. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research note on Friday, August 4th. BMO Capital Markets reissued a “sell” rating and issued a $73.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. TheStreet raised shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. UBS AG lowered shares of Eli Lilly and to a “hold” rating and set a $85.00 price target for the company. in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. lowered shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target for the company. in a research report on Wednesday, July 26th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly and presently has an average rating of “Hold” and a consensus target price of $88.27.
In related news, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00. Following the transaction, the insider now directly owns 124,265,804 shares in the company, valued at $10,491,761,831.72. The disclosure for this sale can be found here. Insiders have sold a total of 669,733 shares of company stock worth $55,845,287 over the last three months. 0.20% of the stock is owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.